Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: A systematic review and meta-analysis

Gene

Volumn 530, Issue 2, 2013, Pages 309-314

  Ma, Qingtong ^a   Qi, Can ^b   Tie, Chong ^c   Guo, Zhanjun ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Epidemiology; Meta analysis; Polymorphism; Prostate cancer; XPD

Indexed keywords

XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CANCER SUSCEPTIBILITY; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLE SIZE; SYSTEMATIC REVIEW;

EID: 84884533391     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.053     Document Type: Article

References (42)

1. Agalliu I., et al. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control 2010, 21:289-300.
2. Alptekin D., et al. Evaluation of the effects of androgen receptor gene tri-nucleotide repeats and prostate-specific antigen gene polymorphisms on prostate cancer. Genet. Mol. Res. 2012, 11:1424-1432.
3. Bau D.T., et al. Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer. Res. 2007, 27:2893-2896.
4. Braithwaite E., Wu X., Wang Z. Repair of DNA lesions: mechanisms and relative repair efficiencies. Mutat. Res. 1999, 424:207-219.
5. Center M.M., et al. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61:1079-1092.
6. Chen Z.P., et al. Evidence for nucleotide excision repair as a modifying factor of O6-methyl-guanine-DNA methyltransferase-mediated innate chloroethylni-trosourea resistance in human tumor cell lines. Mol. Pharmacol. 1997, 52:815-820.
7. Coin F., Marinoni J.C., Rodolfo C., Fribourg S., Pedrini A.M., Egly J.M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat. Genet. 1998, 20:184-188.
8. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
9. Dhillon V.S., Yeoh E., Fenech M. DNA repair gene polymorphisms and prostate cancer risk in South Australia - results of a pilot study. Urol. Oncol. 2011, 29:641-646.
10. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
11. Gao R., et al. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol. Ther. 2010, 10:13-18.
12. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1513-1530.
13. Guo S.W., Thompson E.A. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992, 48:361-372.
14. Heidenreich A., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 2011, 59:61-71.
15. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
16. Hosseini M., SeyedAlinaghi S., Mahmoudi M., McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta Med. Iran. 2010, 48:61-66.
17. Hsieh C.C., et al. Risk factors for prostate cancer: a case-control study in Greece. Int. J. Cancer 1999, 80:699-703.
18. Ioannidis J.P., Patsopoulos N.A., Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007, 335:914-916.
19. Lavender N.A., et al. No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 2010, 70:113-119.
20. Lunn R.M., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
21. Mandal R.K., et al. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India. DNA Cell Biol. 2010, 29:183-190.
22. Mi Y., et al. Impact of two common xeroderma pigmentosum group D (XPD) gene polymorphisms on risk of prostate cancer. PLoS One 2012, 7(9):e44756.
23. Momparler R.L., Bovenzi V. DNA methylation and cancer. J. Cell. Physiol. 2000, 183:145-154.
24. Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nat. Rev. Cancer 2010, 10:205-212.
25. Ritchey J.D., et al. Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1703-1709.
26. Rybicki B.A., et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13:23-29.
27. Sancar A., Tang M.S. Nucleotide excision repair. Photochem. Photobiol. 1993, 57:905-921.
28. Schaeffer L., et al. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J. 1994, 13:2388-2392.
29. Shen M.R., Jones I.M., Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998, 58:604-608.
30. Shen H., Wang L., Spitz M.R., Hong W.K., Mao L., Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002, 62:4992-4995.
31. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
32. Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 2000, 20:7980-7990.
33. Skoog T., et al. A common functional polymorphism (C3A substitution at position-863) in the promoter region of the tumor necrosis factor (TNF-) gene associated with reduced circulating levels of TNF-. Hum. Mol. Genet. 1999, 8:1443-1449.
34. Skoog T., et al. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the tumor necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum. Mol. Genet. 1999, 8:1443-1449.
35. Sobti R.C., et al. Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Mol. Cell. Biochem. 2012, 362:263-268.
36. Taylor E.M., et al. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:8658-8663.
37. Weeda G., Hoeijmakers J.H. Genetic analysis of nucleotide excision repair in mammalian cells. Semin. Cancer Biol. 1993, 4:105-117.
38. Winkler G.S., et al. TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair. J. Biol. Chem. 2000, 275:4258-4266.
39. Witte J.S. Prostate cancer genomics: towards a new understanding. Nat. Rev. Genet. 2009, 10:77-82.
40. Woolf B. On estimating the relation between blood group and disease. Ann. Hum. Genet. 1955, 19:251-253.
41. Xu B., et al. IL-6-174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol. Biol. Rep. 2011, 38:2589-2596.
42. Zhu S., Zhang H., Tang Y., Wang J. Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis. Urol. Int. 2012, 89(2):233-240.